An exciting trial for patients with chondrosarcoma is opening at hospitals across the country.
|Dr. Jon Trent|
Imatinib, a k a Gleevec, is a landmark in the targeted treatment of sarcoma, helping keep people with gastrointestinal stromal tumors (GISTs) alive for years. It was originally developed for chronic myelogenous leukemia (CML).
Sarcoma researchers are looking at drugs used to treat leukemia because both cancers arise from mesenchymal cells. At the annual meeting of the Connective Tissue Oncology Society last fall, physicians joked that “leukemia is just sarcoma of the blood.”
|Miriam Zimms in therapy.|
Agios Pharmaceuticals is sponsoring the new trial, called the "Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation."
"If effective, this drug will bind to the mutant IDH-1 and turn it off, just like turning off a light switch. This would result in the cancer cells turning back into normal cells. I think this stands a very good chance at helping a lot of people affected by chondrosarcoma.
"I am happy to see any patient with chondrosarcoma at our Sarcoma Center. The patient's tumor must have an IDH-1 mutation, which we test for routinely at our institution."
Read the details of the clinical trial here to see if you may be eligible. Patients can call (305) 243-1287 or (305) 243-1000 for an appointment with Dr. Trent.